MCID: SLV003
MIFTS: 45

Salivary Gland Disease

Categories: Oral diseases, Endocrine diseases

Aliases & Classifications for Salivary Gland Disease

MalaCards integrated aliases for Salivary Gland Disease:

Name: Salivary Gland Disease 12 54 15
Salivary Gland Disorders 76 43
Salivary Gland Diseases 55 73
Non-Neoplastic Salivary Gland Disorder 73
Non-Neoplastic Salivary Gland Disease 12

Classifications:



External Ids:

Disease Ontology 12 DOID:10854
ICD9CM 35 527.8

Summaries for Salivary Gland Disease

NINDS : 54 Cytomegalovirus (CMV) is a virus found throughout the world that infects between 50 to 80 percent of all adults in the United States by the age of 40.  CMV is in the same family of viruses that causes cold sores (herpes simplex virus), infectious mononucleosis (Epstein-Barr virus), and chickenpox/shingles (varicella zoster virus).    Most people who acquire CVM as children or adults display no signs of illness or have mild symptoms such as fever, fatigue, or tender lymph nodes.  People with a compromised immune system may have more severe forms of infection involving the nervous system. A hallmark of CMV infection is that the virus cycles through periods of dormancy and active infection during the life of the individual  Infected persons of any age periodically shed the virus in their body fluids, such as saliva, urine, blood, tears, semen, or breast milk.  CMV is most commonly transmitted when infected body fluids come in contact with the mucous membranes of an uninfected person, but the virus can also pass from mother to fetus during pregnancy.  

MalaCards based summary : Salivary Gland Disease, also known as salivary gland disorders, is related to lupus erythematosus and sialadenitis, and has symptoms including halitosis, oral manifestations and snoring. An important gene associated with Salivary Gland Disease is CDSN (Corneodesmosin), and among its related pathways/superpathways are NF-kappaB Signaling and Primary immunodeficiency. The drugs Calcium Carbonate and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include salivary gland, eye and lung.

MedlinePlus : 43 Your salivary glands are in your mouth. You have three pairs of major salivary glands and hundreds of small (minor) glands. They make saliva (spit) and empty it into your mouth through openings called ducts. Saliva makes your food moist, which helps you chew and swallow. It helps you digest your food. It also cleans your mouth and contains antibodies that can kill germs. Problems with salivary glands can cause them to become irritated and swollen. You may have symptoms such as A bad taste in your mouth Difficulty opening your mouth Dry mouth Pain in your face or mouth Swelling of your face or neck Causes of salivary gland problems include infections, obstruction, or cancer. Problems can also be due to other disorders, such as mumps or Sjogren's syndrome.

Wikipedia : 76 Salivary gland diseases (SGD) are multiple and varied in... more...

Related Diseases for Salivary Gland Disease

Diseases related to Salivary Gland Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 146)
# Related Disease Score Top Affiliating Genes
1 lupus erythematosus 29.6 CD40LG TRIM21 TROVE2
2 sialadenitis 27.0 AQP5 CDSN CNTROB HSPG2 RAG1 TNFSF13B
3 igg4-related disease 10.9
4 mononeuritis multiplex 10.9 CD40LG CDSN
5 mononeuritis of upper limb and mononeuritis multiplex 10.9 CD40LG CDSN
6 facial hemiatrophy 10.9 CD40LG TRIM21
7 transient neonatal thrombocytopenia 10.9 CD79A TRIM21
8 zika fever 10.8 AQP5 CD40LG
9 transient neonatal neutropenia 10.8 CD79A TRIM21
10 selective igg deficiency disease 10.8 CD40LG CD79A
11 c1q nephropathy 10.8 CD40LG CD79A
12 meningovascular neurosyphilis 10.8 CD40LG CD79A
13 alpha chain disease 10.8 CD40LG CD79A
14 brill-zinsser disease 10.8 CD40LG CD79A
15 exudative glomerulonephritis 10.8 CD40LG CD79A
16 cork-handlers' disease 10.8 CD40LG CD79A
17 salpingo-oophoritis 10.8 CD40LG CD79A
18 early yaws 10.8 CD40LG CD79A
19 ventilation pneumonitis 10.8 CD40LG CD79A
20 axillary adenitis 10.8 CD40LG CD79A
21 cryofibrinogenemia 10.8 CD40LG CD79A
22 trichostrongyloidiasis 10.8 CD40LG CD79A
23 subacute bacterial endocarditis 10.8 CD40LG CD79A
24 mononeuropathy 10.8 CD40LG CDSN
25 heterophyiasis 10.8 CD40LG CD79A
26 immunoglobulin g deficiency 10.8 CD40LG CD79A
27 orbital granuloma 10.8 CD40LG CD79A
28 transient hypogammaglobulinemia of infancy 10.8 CD40LG CD79A
29 gastroduodenitis 10.8 CD40LG CD79A
30 bacterial conjunctivitis 10.8 CD40LG CD79A
31 heavy chain disease 10.8 CD40LG CD79A
32 ophthalmia neonatorum 10.8 CD40LG CD79A
33 immunoglobulin a deficiency 1 10.8 CD40LG CD79A
34 cerebral arteritis 10.8 CD40LG CD79A
35 selective immunoglobulin deficiency disease 10.8 CD40LG CD79A
36 geniculate herpes zoster 10.8 CD40LG CD79A
37 erythema elevatum diutinum 10.8 CD40LG CD79A
38 sporotrichosis 10.8 CD40LG CD79A
39 fallopian tube disease 10.8 CD40LG CD79A
40 hyperimmunoglobulin syndrome 10.8 CD40LG CD79A
41 congenital syphilis 10.8 CD40LG CD79A
42 polyclonal hypergammaglobulinemia 10.8 CD40LG CD79A
43 monoclonal paraproteinemia 10.8 CD40LG CD79A
44 salpingitis 10.8 CD40LG CD79A
45 ocular toxoplasmosis 10.8 CD40LG CD79A
46 dysgammaglobulinemia 10.8 CD40LG CD79A
47 congenital hypogammaglobulinemia 10.8 CD40LG CD79A
48 acute maxillary sinusitis 10.8 CD40LG CD79A
49 chronic polyneuropathy 10.8 CD40LG CD79A
50 spinocerebellar ataxia, autosomal recessive 10 10.8 CD40LG CD79A

Graphical network of the top 20 diseases related to Salivary Gland Disease:



Diseases related to Salivary Gland Disease

Symptoms & Phenotypes for Salivary Gland Disease

UMLS symptoms related to Salivary Gland Disease:


halitosis, oral manifestations, snoring

Drugs & Therapeutics for Salivary Gland Disease

Drugs for Salivary Gland Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 334)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Calcium Carbonate Approved, Investigational Phase 4 471-34-1
2
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
3
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 22916-47-8 4189
4
Prednisone Approved, Vet_approved Phase 4,Phase 2 53-03-2 5865
5
Ephedrine Approved Phase 4,Phase 3,Phase 2,Not Applicable 299-42-3 9294
6
Pseudoephedrine Approved Phase 4,Phase 3,Phase 2,Not Applicable 90-82-4 7028
7
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Not Applicable 9004-61-9 53477741
8
Cevimeline Approved Phase 4,Not Applicable 107233-08-9 83898 25137844
9
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492
10
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2 50-02-2 5743
11
Pilocarpine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 54-71-7, 92-13-7 5910
12
Oxybutynin Approved, Investigational Phase 4,Phase 2 5633-20-5 4634
13
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 4,Phase 2 53-43-0 9860744
14
Ginseng Approved, Investigational, Nutraceutical Phase 4 50647-08-0
15
Castor oil Approved, Investigational, Nutraceutical, Vet_approved Phase 4 8001-79-4
16 Gallopamil Investigational Phase 4 16662-47-8
17 Antacids Phase 4,Phase 2,Not Applicable
18 Antifungal Agents Phase 4,Phase 2,Phase 1
19 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Anti-Inflammatory Agents Phase 4,Phase 2,Not Applicable
21 Antineoplastic Agents, Hormonal Phase 4,Phase 2
22 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
23 Anti-Ulcer Agents Phase 4,Phase 2,Not Applicable
24 Calcineurin Inhibitors Phase 4,Phase 2
25 Calcium, Dietary Phase 4,Not Applicable
26 Cyclosporins Phase 4,Phase 2,Not Applicable
27 Dermatologic Agents Phase 4,Phase 2,Not Applicable
28 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Not Applicable
29 glucocorticoids Phase 4,Phase 2
30 Hormone Antagonists Phase 4,Phase 2,Not Applicable
31 Hormones Phase 4,Phase 2,Not Applicable
32 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Not Applicable
33 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
34 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Cholinergic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
38 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
39 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Tetrahydrozoline Phase 4,Phase 3,Phase 2,Not Applicable
41 Nasal Decongestants Phase 4,Phase 3,Phase 2,Not Applicable
42 Ophthalmic Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Vasoconstrictor Agents Phase 4,Phase 3,Phase 2,Not Applicable
46 Protective Agents Phase 4,Phase 3,Phase 2,Not Applicable
47 Viscosupplements Phase 4,Phase 3,Not Applicable
48 Carbopol 940 Phase 4,Not Applicable
49 Cathartics Phase 4
50 Laxatives Phase 4

Interventional clinical trials:

(show top 50) (show all 388)
# Name Status NCT ID Phase Drugs
1 Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome Unknown status NCT02370550 Phase 4 Cyclosporin A;Prednisone;Placebo;Calcium carbonate D
2 Stereotactic Body Radiotherapy for Head and Neck Tumors Unknown status NCT01344356 Phase 4
3 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
4 Sex Steroids in Sjögren's Syndrome: Effect of Substitution Treatment on Fatigue Unknown status NCT00543166 Phase 4 dehydroepiandrosterone
5 Effects of Mucoprotective Product on Xerostomia Completed NCT01316393 Phase 4
6 Effect of Korean Red Ginseng (KRG) on Dry Mouth Completed NCT00911768 Phase 4
7 Evaluation of an Electro-stimulator for the Treatment of Xerostomia Completed NCT00509808 Phase 4
8 Study of the Effectiveness of Cevimeline on Oral Health in Patients With Radiation Induced Xerostomia Completed NCT00466388 Phase 4 Cevimeline
9 Quality of Life and Sjögren Syndrome Completed NCT03578900 Phase 4 Xeros;Citric Acid based Mouthwash
10 Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella Vaccine Completed NCT02880865 Phase 4
11 A New Oral salIvary equivAlent Compared to Two moisturizinG Mouth sprAys in Patients With xeRostomiA: NIAGARA Study Completed NCT02049112 Phase 4
12 Safety Study of the Use of Topical Cyclosporine in the Treatment of Dry Eye Disease Completed NCT02004067 Phase 4 Restasis;Refresh Endura
13 Treatment of Dry Eye Using 0.03% Tacrolimus Eye Drops Completed NCT01850979 Phase 4 Tacrolimus;Olive Oil
14 Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations Completed NCT01777529 Phase 4
15 Assessment of Inflammatory Biomarkers Expressed in a Sjogren's Population: Effect of a Topical Steroid Intervention Completed NCT00631358 Phase 4 Maxidex
16 A Comparison of Orally Pilocarpine and Artificial Saliva in Xerostomy Treatment Completed NCT00438048 Phase 4 Artificial Saliva
17 Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine Completed NCT00313950 Phase 4
18 Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Completed NCT00126997 Phase 4
19 Effect of Pilocarpine in Patients With Xerostomia Recruiting NCT02982577 Phase 4 Pilocarpine
20 Evaluation of Influenza A/H3N2 Vaccine in Patients With Rheumatologic Diseases Recruiting NCT03540823 Phase 4
21 Evaluate the Efficacy and Safety of LO2A Eye Drops for Symptomatic Improvement of Dry Eye in Patients With Sjögren's Syndrome Recruiting NCT03319420 Phase 4 LO2A eye drops;Systane Ultra UD
22 Use of Biotene Moisturizing Mouth Spray for Xerostomia Associated With Oral Oxybutynin Use Not yet recruiting NCT02522936 Phase 4 Biotene oral spray
23 Parotid-Sparing Intensity-Modulated Radiation Therapy Compared With Conventional Radiation Therapy in Treating Patients With Oropharyngeal or Hypopharyngeal Cancer Who Are at High Risk of Radiation-Induced Xerostomia Unknown status NCT00081029 Phase 3
24 Platelet -Rich Plasma (PRP) Injection for the Treatment of Severe Dry Eye Unknown status NCT02257957 Phase 3 PRP injection;Standard care Hyaluronic acid eye drops
25 Study of I-125 Brachytherapy Versus Intensity-modulated Radiation Therapy to Treat Inoperable Salivary Gland Cancer Unknown status NCT02048254 Phase 3
26 Efficacy of Tocilizumab in Primary Sjögren's Syndrome. Unknown status NCT01782235 Phase 2, Phase 3 Tocilizumab;Placebo
27 Application of Botulinum Toxin Type A in Salivary Glands in the Treatment of Drooling in Patients With Cerebral Palsy Unknown status NCT01489904 Phase 2, Phase 3
28 Treatment of Salivary Gland Hypofunction With Neuro- Electrostimulation Unknown status NCT01174329 Phase 2, Phase 3
29 Intensity-Modulated Radiation Therapy or 3-Dimensional Conformal Radiation Therapy in Decreasing Hearing Loss in Patients Who Have Undergone Surgery for Parotid Tumors Unknown status NCT01216800 Phase 3
30 Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adults Completed NCT02610868 Phase 3 MYOBLOC
31 Botulinum Toxin-A for Sialorrhoea Treatment in Asian Adults With Neurological Diseases Completed NCT02425176 Phase 2, Phase 3 Botulinum toxin A (BoNT-A) 50U;Botulinum toxin A (BoNT-A) 100U;Botulinum toxin A (BoNT-A) 200U
32 Metoclopramide as Treatment of Clozapine-induced Hypersalivation Completed NCT02222220 Phase 3 Metoclopramide;placebo
33 Efficacy and Safety Study of MYOBLOC® Followed by Open-Label Multiple-Treatment With MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adult Subjects Completed NCT01994109 Phase 3 MYOBLOC
34 Drug-induced Xerostomia. Evaluation of Malic Acid 1%, Salivary Mucins and Buffering Capacity Completed NCT01652001 Phase 2, Phase 3 Malic Acid
35 Benzamide Derivates as Treatment of Clozapine-induced Hypersalivation Completed NCT00534573 Phase 3 Amisulpride, Moclobemide
36 A Trial Looking at Treating Dry Mouth After Radiotherapy for Head and Neck Cancer Completed NCT02941276 Phase 3
37 Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00656513 Phase 2, Phase 3 Pilocarpine
38 Trial Comparing Oral Pilocarpine (Salagen) Versus Submandibular Salivary Gland Transfer Protocol, For the Prevention of Radiation (XRT) Induced Xerostomia in Head and Neck Cancer Patients Completed NCT00168181 Phase 3 Salagen
39 Intravenous Versus Subcutaneous Amifostine in Prevention of Xerostomia After RT for Head and Neck Carcinomas Completed NCT00158691 Phase 3 Ethyol
40 Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy Infants Completed NCT02692599 Phase 3
41 A Phase III Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome Completed NCT02503189 Phase 3 KCT-0809 ophthalmic solution;Placebo
42 A Long-term Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome Completed NCT02503163 Phase 3 KCT-0809 ophthalmic solution
43 Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age Completed NCT02184572 Phase 3
44 Clinical Study to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 Versus Placebo in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions Completed NCT02091739 Phase 3 IncobotulinumtoxinA (100 Units);IncobotulinumtoxinA (75 Units);Placebo
45 Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older Completed NCT02058563 Phase 3
46 Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months. Completed NCT01991899 Phase 3
47 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life Completed NCT01681992 Phase 3
48 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age Completed NCT01621802 Phase 3
49 Hydroxychloroquine Treatment of Dry Eyes in Patients With Primary Sjögren's Syndrome Completed NCT01601028 Phase 3 Hydroxychloroquine;Placebo
50 Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027) Completed NCT01536405 Phase 3

Search NIH Clinical Center for Salivary Gland Disease

Genetic Tests for Salivary Gland Disease

Anatomical Context for Salivary Gland Disease

MalaCards organs/tissues related to Salivary Gland Disease:

41
Salivary Gland, Eye, Lung, Lymph Node, Brain, Testes, Kidney

Publications for Salivary Gland Disease

Articles related to Salivary Gland Disease:

(show top 50) (show all 71)
# Title Authors Year
1
Distinct BK polyomavirus non-coding control region (NCCR) variants in oral fluids of HIV- associated Salivary Gland Disease patients. ( 27085139 )
2016
2
Oral mucocele/ranula: Another human immunodeficiency virus-related salivary gland disease? ( 25446909 )
2014
3
Salivary gland disease in SjAPgren's syndrome: sialoadenitis to lymphoma. ( 24287195 )
2014
4
HIV-associated salivary gland disease - clinical or imaging diagnosis? ( 25187268 )
2014
5
Human prominin-1 (CD133) is detected in both neoplastic and non-neoplastic salivary gland diseases and released into saliva in a ubiquitinated form. ( 24911657 )
2014
6
Focused review of investigation, management and outcomes of salivary gland disease in specialty-specific journals. ( 24792858 )
2014
7
Salivary gland diseases: infections, sialolithiasis and mucoceles. ( 24862601 )
2014
8
Is sialendoscopy an effective treatment for obstructive salivary gland disease? ( 23404254 )
2013
9
Natural killer cells regulate murine cytomegalovirus-induced sialadenitis and salivary gland disease. ( 22156514 )
2012
10
Sialendoscopy for the management of obstructive salivary gland disease: a systematic review and meta-analysis. ( 22710505 )
2012
11
Viruses and salivary gland disease (SGD): lessons from HIV SGD. ( 21441486 )
2011
12
Salivary gland disease. ( 20428015 )
2010
13
Diagnostic discussion. HIV-associated salivary gland disease (HIVSGD)-HIV related parotid cysts. ( 20443533 )
2010
14
HIV-associated salivary gland disease. ( 19608050 )
2009
15
Recent advances in the management of salivary gland disease. ( 19651463 )
2009
16
Clinical implications of the neck in salivary gland disease. ( 18603202 )
2008
17
A revolution in the management of obstructive salivary gland disease. ( 16512096 )
2006
18
Advances in the treatment of salivary gland disease. ( 17194041 )
2006
19
Modern management of obstructive salivary gland disease. ( 16479855 )
2004
20
Clinical conditions and lesions mimicking salivary gland disease: Part 2. ( 15633830 )
2004
21
Salivary gland disease in pediatric HIV patients: an update. ( 15272653 )
2004
22
Clinical conditions and lesions mimicking salivary gland disease, part 1. ( 15622887 )
2004
23
Salivary gland disease in HIV/AIDS and primary SjAPgren's syndrome: analysis of collagen I distribution and histopathology in American and African patients. ( 12969229 )
2003
24
The genu of the submandibular duct--is the angle significant in salivary gland disease? ( 11803383 )
2002
25
The role of MRI in facial swelling due to presumed salivary gland disease. ( 11718383 )
2001
26
Benign salivary gland disease. ( 11480124 )
2001
27
Diagnosing salivary gland disease. ( 11462349 )
2001
28
Imaging of salivary gland disease. ( 10670049 )
2000
29
Salivary gland disease in human immunodeficiency virus-positive women from the WIHS study. Women's Interagency HIV Study. ( 10846124 )
2000
30
Bilateral and multicystic major salivary gland disease: a rare presentation of primary SjAPgren's syndrome. ( 10209623 )
1998
31
The surgical management of salivary gland disease of the sublingual gland and floor of mouth. ( 11905350 )
1998
32
Lupus erythematosus profundus around the salivary glands: a case resembling submandibular salivary gland disease. ( 9229369 )
1997
33
An association between salivary gland disease and serological abnormalities in SjAPgren's syndrome. ( 9385581 )
1997
34
Salivary autoantibodies in HIV-associated salivary gland disease. ( 8315599 )
1993
35
HIV-salivary gland disease. Salivary scintiscanning with technetium pertechnetate. ( 8394560 )
1993
36
Ultrasonography in the investigation of salivary gland disease. ( 8299828 )
1993
37
Ultrasound in salivary gland disease. ( 8397364 )
1993
38
Sialochemistry in human immunodeficiency virus associated salivary gland disease. ( 1556696 )
1992
39
Salivary gland disease in infancy and childhood: non-malignant lesions. ( 1494185 )
1992
40
Spectrum of salivary gland disease in HIV-infected patients: characterization with Ga-67 citrate imaging. ( 1509064 )
1992
41
Natural history of HIV-associated salivary gland disease. ( 1407995 )
1992
42
Serum anti-SS-B/La and IgA rheumatoid factor are markers of salivary gland disease activity in primary SjAPgren's syndrome. ( 1445455 )
1992
43
HIV-associated salivary gland disease: a review. ( 1549310 )
1992
44
Salivary gland disease in dogs and cats: 245 cases (1985-1988). ( 2010345 )
1991
45
Oral medicine in practice: salivary gland disease. ( 2182095 )
1990
46
An approach to the diagnosis and management of salivary gland disease. ( 2721417 )
1989
47
Clinical assessment and diagnosis of immunologically mediated salivary gland disease in SjAPgren's syndrome. ( 2789655 )
1989
48
Diagnosis of salivary gland disease using ultrasound and sialography: a comparison. ( 2545387 )
1989
49
Does HIV cause salivary gland disease? ( 2517203 )
1989
50
Technetium-99m pertechnetate and gallium-67 imaging in salivary gland disease. ( 2548796 )
1989

Variations for Salivary Gland Disease

Expression for Salivary Gland Disease

Search GEO for disease gene expression data for Salivary Gland Disease.

Pathways for Salivary Gland Disease

Pathways related to Salivary Gland Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.77 CD40LG CD79A RAG1 TNFSF13B
2 10.37 CD40LG CD79A RAG1

GO Terms for Salivary Gland Disease

Biological processes related to Salivary Gland Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 B cell proliferation GO:0042100 9.16 CD40LG CD79A
2 B cell differentiation GO:0030183 9.13 CD40LG CD79A RAG1
3 immunoglobulin secretion GO:0048305 8.62 CD40LG TNFSF13B

Molecular functions related to Salivary Gland Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 tumor necrosis factor receptor binding GO:0005164 8.62 CD40LG TNFSF13B

Sources for Salivary Gland Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....